Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.

Doussau A, Thiébaut R, Paoletti X.

Stat Med. 2013 Dec 30;32(30):5430-47. doi: 10.1002/sim.5960. Epub 2013 Sep 10.

PMID:
24018535
2.

Dose finding with longitudinal data: simpler models, richer outcomes.

Paoletti X, Doussau A, Ezzalfani M, Rizzo E, Thiébaut R.

Stat Med. 2015 Sep 30;34(22):2983-98. doi: 10.1002/sim.6552. Epub 2015 Jun 24.

PMID:
26109523
3.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

Doussau A, Thiébaut R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X.

Ann Oncol. 2015 Feb;26(2):422-8. doi: 10.1093/annonc/mdu523. Epub 2014 Nov 17.

PMID:
25403589
4.

A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Paoletti X, Kramar A.

Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682.

PMID:
19672839
5.

Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.

Paoletti X, Baron B, Schöffski P, Fumoleau P, Lacombe D, Marreaud S, Sylvester R.

Eur J Cancer. 2006 Jul;42(10):1362-8. Epub 2006 Jun 5.

PMID:
16740385
6.

Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.

Doussau A, Asselain B, Le Deley MC, Geoerger B, Doz F, Vassal G, Paoletti X.

Contemp Clin Trials. 2012 Jul;33(4):657-65. doi: 10.1016/j.cct.2011.11.015. Epub 2012 Apr 13.

PMID:
22521954
7.

Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.

Wages NA, Tait C.

J Biopharm Stat. 2015;25(5):903-20. doi: 10.1080/10543406.2014.920873. Epub 2014 Jun 6.

8.

Optimal phase I dose-escalation trial designs in oncology--a simulation study.

Gerke O, Siedentop H.

Stat Med. 2008 Nov 20;27(26):5329-44. Erratum in: Stat Med. 2008 Nov 20;27(26):5564.

PMID:
17849502
9.

Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.

Colin P, Micallef S, Delattre M, Mancini P, Parent E.

Stat Med. 2015 Sep 30;34(22):2999-3016. doi: 10.1002/sim.6548. Epub 2015 Jun 8.

PMID:
26059319
10.

Dose finding with continuous outcome in phase I oncology trials.

Wang Y, Ivanova A.

Pharm Stat. 2015 Mar-Apr;14(2):102-7. doi: 10.1002/pst.1662. Epub 2014 Nov 19.

PMID:
25408518
11.

Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.

Van Meter EM, Garrett-Mayer E, Bandyopadhyay D.

Clin Trials. 2012 Jun;9(3):303-13. doi: 10.1177/1740774512443593. Epub 2012 Apr 30.

PMID:
22547420
12.

Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.

Van Meter EM, Garrett-Mayer E, Bandyopadhyay D.

Stat Med. 2011 Jul 30;30(17):2070-80. doi: 10.1002/sim.4069. Epub 2011 Feb 23.

13.

New adaptive method for phase I trials in oncology.

Meille C, Gentet JC, Barbolosi D, André N, Doz F, Iliadis A.

Clin Pharmacol Ther. 2008 Jun;83(6):873-81. Epub 2007 Oct 24.

PMID:
17957185
14.

Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.

Thall PF, Lee SJ.

Int J Gynecol Cancer. 2003 May-Jun;13(3):251-61. Review.

PMID:
12801254
15.

Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.

Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC.

Stat Med. 2013 Jul 20;32(16):2728-46. doi: 10.1002/sim.5737. Epub 2013 Jan 21.

16.

Critical aspects of the Bayesian approach to phase I cancer trials.

Neuenschwander B, Branson M, Gsponer T.

Stat Med. 2008 Jun 15;27(13):2420-39. doi: 10.1002/sim.3230.

PMID:
18344187
17.

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer..

Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2.

PMID:
18602257
18.

Competing designs for drug combination in phase I dose-finding clinical trials.

Riviere MK, Dubois F, Zohar S.

Stat Med. 2015 Jan 15;34(1):1-12. doi: 10.1002/sim.6094. Epub 2014 Jan 27.

PMID:
24464821
19.

Dose-finding design driven by efficacy in onco-hematology phase I/II trials.

Seegers V, Chevret S, Resche-Rigon M.

Stat Med. 2011 Jun 15;30(13):1574-83. doi: 10.1002/sim.4152. Epub 2011 Mar 11.

PMID:
21394754
20.

Supplemental Content

Support Center